Award Number: W81XWH-12-1-0503

TITLE: Tuft Cell Regulation of miRNAs in Pancreatic Cancer

PRINCIPAL INVESTIGATOR: Courtney W. Houchen

CONTRACTING ORGANIZATION: The University of Oklahoma Health Sciences Center
Oklahoma City, OK 73104

REPORT DATE: December 2014

TYPE OF REPORT: Final Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Tuft Cell Regulation of miRNAs in Pancreatic Cancer

To better understand the role of tuft cells in the pancreas and to define their effects on the pancreatic body as well as the initiation of pancreatic cancer. Tuft cells are present in the hollow organs of the digestive and respiratory tracts. They are characterized by long and blunt microvilli with prominent rootlets and by a well-developed tubulovesicular system in the supranuclear cytoplasm. Recent reports suggest that tuft cells may act as mechanoreceptors and are involved in chemosensensing of the microenvironment. With the successful deletion of Dclk1 throughout the pancreatic ducts, we have characterized, which extends our understanding of the role tuft cells play within ducts and their broader effects on the overall pancreatic microenvironment. We observed that Dclk1 co-localized with other putative tuft cell markers including Cox1 and Cox2. Additionally, we also observed the presence of the tuft cells of wild type and Pdx-1-Cre;Dclk1floxtm1 mice, indicating that Dclk1 may not play a role in tuft cells at baseline. We performed additional experiments to demonstrate the role of Dclk1 in pancreatic inflammation leading to pancreatic neoplasia. Dclk1 played a vital role in governing and is essential for pancreatic inflammatory process and associated metastatic progression following caerulein-induced acinar ductal metaplasia. These finding could very well provide the basis for the development of novel chemotherapeutic drugs targeting these specialized cells expressing Dclk1 for eradication of pancreatitis and pancreatic adenocarcinoma. The data generated from this DoD grant played a major role in securing a successful R01 (1R01 CA182869 01A1), one scientific research publication (PLoS One. 2015 Feb 27;10(2):e0118933), and one scientific presentation at the 2014 American Pancreatic Association conference (Pancreas. 2014 43(8):1389-90).
## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>2</td>
</tr>
<tr>
<td>Body</td>
<td>2</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>3</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>3</td>
</tr>
<tr>
<td>Conclusion</td>
<td>4</td>
</tr>
<tr>
<td>References</td>
<td>4</td>
</tr>
<tr>
<td>Appendices</td>
<td>5</td>
</tr>
<tr>
<td>Supporting Data</td>
<td>7</td>
</tr>
</tbody>
</table>
INTRODUCTION: To better understand the role of tuft cells in the pancreas and to define their effects on the pancreatic body as well as the initiation of pancreatic cancer. Tuft cells are present in the hollow organs of the digestive and respiratory tracts. They are characterized by long and blunt microvilli with prominent rootlets and by a well-developed tubulovesicular system in the supranuclear cytoplasm. Recent reports suggest that tuft cells may act as mechanoreceptors and are involved in chemosensensing of the microenvironment.

BODY:

Aim/Task 1: To characterize tuft cell expression in the mouse pancreas. (1 – 12 months)

Tasks 1a and b: The initial breeding for the generation of the proposed p46cre;KRASG12D mouse model proved problematic and the rate of genotypically desirably offspring was not consistent with expected and proposed results. The animals numbers needed would not be reached at an appropriate time for the completed of proposed work. Therefore we sought to replace the current p48cre breeding stock with newly acquired Pdx-1-Cre;KRASG12D mice. As per the proposal, we characterized the tuft cells in pancreatic tissues in the presence and absence of Dclk1. In the wild type mice, we did find the co-localization of Dclk1 with Cox1, Cox2, and other tuft cell markers (Figure 1) in all age groups.

Aim/Task 2: To determine the role of Dclk1 (DCAMKL-1) in pancreatic tuft cell regulation and regulation of miRNAs in tuft cells. (1 – 12 months)

Task 2a: Here we have successfully crossed Pdx-1-Cre to Dclk1flox/flox (formally DCAMKL-1) and created the novel compound mouse model Pdx-1-Cre;Dclk1flox/flox (Dclk1-KO mice).

We performed experiments and confirmed that Dclk1 was in fact deleted from all pancreatic ductal regions as expected from utilizing the Pdx-1-Cre promoter (Figure 1). We have also characterized the expression of other tuft cell markers Cox1 and Cox2 (Figure 1). As said above, in wild type mice there was co-localization of Dclk1 with Cox1 and Cox2. Whereas in Dclk1-KO mice, we still found the presence of other tuft cell markers Cox1 and Cox2 indicating that tuft cells exists in the absence of Dclk1. Furthermore, in the immunelectron microscopy, we did not find any differences in the tuft cells with Dclk1 or absence of Dclk1 (Dclk1-KO mice). Additionally, also observed the presence of tuft cells in Dclk1-KO mice with KRAS mutation. This indicates that the absence of Dclk1 embryonically did not change the outcome/nature of the tuft cell.

Task 2b: Following the recent successful creation and characterization of the Pdx-1-Cre;Dclk1flox/flox compound mice, completion of this task was achieved. mRNA and miRNA analysis utilizing RT-PCR has been completed for the control mice (WT) and Dclk1-KO mice, we confirmed the absence of Dclk1 mRNA in the mouse pancreas (Data not shown). We performed miRNA analysis of Dclk1+ tuft cells from C57BL/6 wild type mice as proposed in our application. Cells of the pancreata were isolated using
Alexa Fluor conjugated Dclk1 antibody and FACS sorted into ve+ and ve- subpopulations. These subpopulations were then subjected to RT-PCR analysis. We found that Dclk1+ cells had less tumor suppressor miRNAs let-7a, mir-144, and mir-200a (Figure 2). No difference in the ultrastructural investigation of these cell subpopulations was found.

Aim 3: To determine the mechanism by which DCAMKL-1+ tuft cells regulate pancreatic cancer initiation. (12 – 24 months)

For this aim we utilized novel mouse line Pdx-1-Cre;Dclk1\textsuperscript{flox/flox} with the KRAS\textsuperscript{LSL-G12D}. We employed mice from different age groups and compared the pancreatic initiation profile. Profiling included the number and size of the tumors. We expected the Pdx-1-Cre;KRAS\textsuperscript{LSL-G12D} mice will develop rapid pancreatic tumors compared to Pdx-1-Cre;KRAS\textsuperscript{LSL-G12D};Dclk1\textsuperscript{flox/flox} mice. We observed that the pancreatic initiation in both the mouse lines was around 10 months and we did not find any difference between the two groups. This is in-line with the previous published Nature Genetics article where Apc\textsuperscript{min/+} mice with Dclk1 knockout did not show any differences with the polyp or tumor formation [4]. These data taken together indicate that embryonic deletion of Dclk1 does not have any role in pancreatic cancer initiation and progression. Alternatively, another mutation (p53) is required for hastening the cancer initiation process (we have proposed these methods in our newly awarded R01, which is in continuous of our DoD grant proposal.) The preliminary data obtained from this DoD grant played a crucial role in securing the newly awarded R01 (1R01 CA182869 01A1).

KEY RESEARCH ACCOMPLISHMENTS:

- Successful creation of the novel compound mouse Pdx-1-Cre;Dclk1\textsuperscript{flox/flox}.
- Initial characterization of Pdx-1-Cre;Dclk1\textsuperscript{flox/flox} was completed which demonstrated the loss of Dclk1 expression within tuft cells in all pancreatic ducts.
- Successful creation of the novel compound mouse Pdx-1-Cre;KRAS\textsuperscript{LSL-G12D}
- Successful creation and characterization of novel compound mouse Created the novel compound mouse Pdx-1-Cre;KRAS\textsuperscript{LSL-G12D}; Dclk1\textsuperscript{flox/flox}

REPORTABLE OUTCOMES:

- Created the novel compound mouse Pdx-1-Cre;Dclk1\textsuperscript{flox/flox}
- Created the novel compound mouse Pdx-1-Cre;KRAS\textsuperscript{LSL-G12D}
- Created the novel compound mouse Pdx-1-Cre;KRAS\textsuperscript{LSL-G12D}; Dclk1\textsuperscript{flox/flox}
- The data generated from this DoD grant played a major role in securing a successful R01 grant application (1R01 CA182869 01A1 – The role of DCLK1 in the initiation of pancreatic ductal adenocarcinoma, PI: Courtney W. Houchen, April, 2015 – Mar, 2020).
- Successfully published recently in journal PLoS ONE (Qu et al., PLoS One. 2015 Feb 27;10(2):e0118933) [5].
CONCLUSION:

With the successful deletion of Dclk1 throughout the pancreatic ducts, we have characterized, which extends our understanding of the role tuft cells play within ducts and their broader effects on the overall pancreatic microenvironment. We found that Dclk1 co-localizes with other potential tuft cell markers like Cox1, and Cox2 in pancreatic tissues. There is existence of tuft cells in the absence of Dclk1 indicating that at baseline or normal conditions, Dclk1 may not play a role in tuft cells (this is similar to our previous observation that Dclk1 marks a quiescent intestinal stem/tuft cells). In this DoD grant application, we discovered that Dclk1 had a limited role in pancreatic cancer initiation in an embryonically deleted Dclk1 with KRAS mutation. This lead to the conclusion that another mutation (p53) may be required for the initiation of pancreatic cancer and Dclk1 may play a role in pancreatic initiation in the double mutant mice. These studies are proposed in our newly secured R01 grant application.

REFERENCES:


APPENDICES: None
SUPPORTING DATA:

Figure 1: The novel compound mouse model Pdx-1-Cre;Dclk1^flx/flx demonstrates the ductal-specific deletion of Dclk1. Top panel demonstrates the presence of pancreatic duct (H&E) with the expression of Dclk1, Cox1 and Cox2 seen in Pdx-1-Cre control mice (WT). The lower panel also demonstrates a pancreatic duct (H&E), but the notable absence of Dclk1 can be seen (arrow), the continued expression of tuft cell markers Cox1 and Cox2 can also been identified.

Figure 2: Expression of tumor suppressor miRNAs is low in Dclk1^+ pancreatic tuft cells. Pancreatic cells from wild-type C57BL/6 mice were isolated based on the procedure published earlier [1]. Total cells were subjected to Dclk1-based fluorescent activated cell sorting protocols to isolate Dclk1^+ and Dclk1^− cells. Total RNA was isolated from these cells and subjected to Real-time RTPCR analysis for Dclk1 mRNA, and other pri-miRNAs – Let-7a, miR-144, miR-200a. We observed higher levels of Dclk1 mRNA in Dclk1^+ cells compared to Dclk1^− cells. Furthermore, we also observed significantly (p<0.01) lower expression of Let-7a, miR-144 and miR-200a. These results are consistent with our previously published reports indicating that DCLK1 regulates these tumor suppressor miRNAs in human pancreatic cancer cell lines [2, 3].